{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:17:43Z","timestamp":1793042263216,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009086","name":"Medical University-Sofia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.diagmicrobio.2026.117306","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:59:16Z","timestamp":1770253156000},"page":"117306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["In vitro activity of eravacycline compared to other antibiotics commonly used for treatment of infections involving anaerobic bacteria: a review of the literature and our own data"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-0873","authenticated-orcid":false,"given":"Lyudmila","family":"Boyanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Marteva-Proevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliya","family":"Boyanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petyo","family":"Hadzhiyski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raina","family":"Gergova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumyana","family":"Markovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2026.117306_bib0001","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2217\/fmb-2019-0132","article-title":"Multidrug resistance in anaerobes","volume":"14","author":"Boyanova","year":"2019","journal-title":"Future Microbiol"},{"key":"10.1016\/j.diagmicrobio.2026.117306_bib0002","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.anaerobe.2018.06.016","article-title":"In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species","volume":"52","author":"Goldstein","year":"2018","journal-title":"Anaerobe"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2026.117306_bib0003","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10096-019-03590-3","article-title":"Eravacycline, a newly approved fluorocycline","volume":"38","author":"Lee","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117306_bib0004","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117306_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clinmicnews.2023.04.001","article-title":"Review of novel third-generation tetracyclines: eravacycline, omadacycline, and sarecycline","volume":"45","author":"Kim","year":"2023","journal-title":"Clin Microbiol Newsl"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117306_bib0006","doi-asserted-by":"crossref","first-page":"e02206","DOI":"10.1128\/AAC.02206-17","article-title":"Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates","volume":"62","author":"Snydman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117306_bib0007","article-title":"Comparative efficacy of eravacycline and tigecycline in addressing multidrug-resistant gram-negative bacteria","volume":"3","author":"Zhang","year":"2025","journal-title":"One Health Adv"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117306_bib0008","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/jac\/dkae220","article-title":"Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus","volume":"79","author":"Jing","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2026.117306_bib0009","unstructured":"EUCAST, The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0, 2025. https:\/\/www.eucast.org."},{"issue":"10","key":"10.1016\/j.diagmicrobio.2026.117306_bib0010","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/jac\/dkaa289","article-title":"In vitro activity of eravacycline against common ribotypes of Clostridioides difficile","volume":"75","author":"Bass\u00e8res","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117306_bib0011","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/antibiotics12010063","article-title":"Antimicrobial susceptibility profile of rare anaerobic bacteria","volume":"12","author":"Wolf","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.diagmicrobio.2026.117306_bib0012","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgar.2024.03.014","article-title":"Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: a clinical microbiological study","volume":"37","author":"Tsai","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117306_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2020.1848158","article-title":"Gut Bacteroides species in health and disease","volume":"13","author":"Zafar","year":"2021","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117306_bib0014","doi-asserted-by":"crossref","DOI":"10.1080\/20002297.2022.2079814","article-title":"Prevotella species as oral residents and infectious agents with potential impact on systemic conditions","volume":"14","author":"K\u00f6n\u00f6nen","year":"2022","journal-title":"J Oral Microbiol"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117306_bib0015","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3390\/microorganisms11092358","article-title":"The role of Fusobacterium nucleatum in oral and colorectal carcinogenesis","volume":"11","author":"Pignatelli","year":"2023","journal-title":"Microorganisms"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117306_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00135-23","article-title":"Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options","volume":"37","author":"Di Bella","year":"2024","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117306_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00064-21","article-title":"Large clostridial toxins: mechanisms and roles in disease","volume":"85","author":"Orrell","year":"2021","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.diagmicrobio.2026.117306_bib0018","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2217\/fmb-2022-0191","article-title":"Cutibacterium acnes (formerly Propionibacterium acnes): friend or foe?","volume":"18","author":"Boyanova","year":"2023","journal-title":"Future Microbiol"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117306_bib0019","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/microorganisms9081665","article-title":"In vitro antimicrobial susceptibility profiles of gram-positive anaerobic cocci responsible for human invasive infections","volume":"9","author":"Gu\u00e9rin","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.diagmicrobio.2026.117306_bib0020","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jgar.2021.10.020","article-title":"A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals","volume":"29","author":"Hobbs","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117306_bib0021","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/dkaa386","article-title":"Eravacycline, a novel tetracycline derivative, does not induce clostridioides difficile infection in an in vitro human gut model","volume":"76","author":"Buckley","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117306_bib0022","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14787210.2024.2351552","article-title":"Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications","volume":"22","author":"Huang","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117306_bib0023","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1080\/07853890.2022.2085881","article-title":"Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance","volume":"54","author":"LaPlante","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.diagmicrobio.2026.117306_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107314","article-title":"Outcomes of adjunctive eravacycline for severe and fulminant Clostridioides difficile infection","volume":"151","author":"Arena","year":"2025","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117306_bib0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archsurg.2009.51","article-title":"Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality","volume":"144","author":"Sailhamer","year":"2009","journal-title":"Arch Surg"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117306_bib0026","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0041-1740973","article-title":"Fulminant Clostridioides difficile infection: a review of treatment options for a life-threatening infection","volume":"43","author":"Carlson","year":"2022","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2026.117306_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2020.102150","article-title":"Activity of delafloxacin versus that of levofloxacin against anaerobic and microaerophilic isolates","volume":"62","author":"Boyanova","year":"2020","journal-title":"Anaerobe"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2026.117306_bib0028","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.7546\/CRABS.2025.11.14","article-title":"Toxigenic Clostridioides difficile and their antibiotic susceptibility in Bulgarian patients during and post-COVID-19 pandemic","volume":"78","author":"Boyanova","year":"2025","journal-title":"C R Acad Bulg Sci"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117306_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02351-23","article-title":"Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022","volume":"12","author":"Kunz Coyne","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.diagmicrobio.2026.117306_bib0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2022.05.020","article-title":"Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"30","author":"Li","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117306_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2023.116006","article-title":"Eravacycline -synergistic activity with other antimicrobials in carbapenem resistant isolates of Escherichia coli and Acinetobacter baumannii","volume":"107","author":"Rahul","year":"2023","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889326000568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889326000568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:12:57Z","timestamp":1771600377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889326000568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0732889326000568"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117306","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of eravacycline compared to other antibiotics commonly used for treatment of infections involving anaerobic bacteria: a review of the literature and our own data","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117306"}}